Cost-effectiveness of galantamine in a German context;Kosteneffektivität von galantamin in Deutschland

Psychiatrische Praxis

Volumn 32, Issue 3, 2005, Pages 142-150

  Happich, Michael ^a   Schweikert, Bernd ^b   Mühlbacher, Axel ^c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Hochschule Neubrandenburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALANTAMINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; GERMANY; HEALTH CARE SYSTEM; HUMAN; MORTALITY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; GALANTAMINE; GERMANY; HUMANS; MALE; MARKOV CHAINS; MENTAL STATUS SCHEDULE; NATIONAL HEALTH PROGRAMS; NOOTROPIC AGENTS; PSYCHOMETRICS; QUALITY-ADJUSTED LIFE YEARS; STATISTICS; SURVIVAL RATE;

EID: 17444395547     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834709     Document Type: Article

References (49)

1. Hallauer HJ, Kurz A (Hrsg). Weißbuch Demenz. Stuttgart: Thieme, 2002
2. Schneider B, Weber B, Maurer K, Frolich L. Problematik der Beurteilung depressiver Symptome Demenzkranker. Psychiat Prax 2002; 29 (2): 76-82
3. Rainer M, Jungwirth S, Kruger-Rainer C, Croy A, Gatterer G, Haushofer M. Pflegende Angehörige von Demenzerkrankten: Belastungsfaktoren und deren Auswirkung. Psychiat Prax 2002; 29 (3): 142-147
4. Arzneimittelkommission der deutschen Ärzteschaft. Demenz. Arzneiverordnung in der Praxis. Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft. 2. Auflage ed. Köln: 2001
5. Gesundheitsbericht für Deutschland. Stuttgart: Metzler-Poeschel, 1998
6. Wormstall H, Schmidt W. Strukturwandel einer Alzheimer- Angehörigengruppe. Psychiat Prax 1997; 24 (3): 117-119
7. Mace N, Rabins P. The 36 hour day: a family guide to caring for persons with Alzheimer's disease, related dementing illnesses, and memory loss later in life. Baltimore, MD: John Hopkins University Press, 1999
8. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev, 2000; 4: CD001191
9. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev, 2003; 3: CD001190
10. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev, 2004; 4: CD001747
11. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin Ther 2004; 26 (5): 615-630
12. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004; 61 (2): 252-256
13. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19 (1): 58-67
14. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20 (10): 777-789
15. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 14 (2): 84-89
16. Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 2001; 57 (6): 972-978
17. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003; 18 (8): 740-747
18. Deutsche Gesellschaft für Psychiatrie und Psychotherapie. Behandlungsleitlinie Demenz. Praxisleitlinien in Psychiatrie und Psychotherapie. Darmstadt: Steinkopff Verlag, 10/2003
19. Fritze J, Saß H, Schmauß M. Befragung der Fachgesellschaften durch den Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen zur Frage von Über-, Unter- und Fehlversorgung: Stellungnahme der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN): Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde 2001.19.2.2001
20. Hallauer JF, Schons M, Smala A, Berger K. Untersuchung von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Ges Ökon Qual Manag 2000; 5: 73-79
21. Bickel H. Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriatr 2001; 34 (2): 108-115
22. Schulenburg JM, Horn R, Grobe-Einsler R, Bernhardt T, Möller H-J, Schulenburg I. Kostenanalyse der Behandlung hirnleistungsgestörter Patienten. Geriatrie Forschung, Zeitschrift für Altersmedizin 1995; 5 (1): 31-40
23. nd ed. Oxford: Oxford Press, 1997
24. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52 (6): 1138-1145
25. Kemeny JG, Snell JL. Finite Markov Chains. New York: Springer-Verlag, 1976
26. Jönsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999; 21 (7): 1230-1240
27. TreeAge. DATA - Healthcare user's manual. Williamstown: TreeAge Software, Inc, 2001
28. Koch HJ, Gurtler K, Fischer-Barnicol D, Szecsey A, Ibach B. Bestimmung der Reliabilität psychometrischer Testverfahren in der Psychiatrie mittels der kanonischen Korrelation. Psychiat Prax 2003; 30, Suppl 2: 157-160
29. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (3): 189-198
30. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359 (9314): 1283-1290
31. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54 (12): 2261-2268
32. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71 (5): 589-595
33. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321 (7274): 1445-1449
34. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 1999; 37 (1): 27-32
35. Novella JL, Jochum C, Jolly D, Morrone I, Ankri J, Bureau F et al. Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res 2001; 10 (5): 443-452
36. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43 (11): 2412-2414
37. O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999; 47 (5): 570-578
38. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc 2002; 50 (1): 35-40
39. Fraser M, Snyder EH. The economic benefits of delaying progression in Alzheimer's disease using cholinesterase inhibitors. Clin Geriatr 2000; 8 (2): 72-93
40. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57 (3): 489-495
41. Statistisches Bundesamt. Statistisches Jahrbuch. Stuttgart: Metzler-Poeschel, 2004
42. Richardi R. Bundes-Angestelltentarifvertrag. München: Deutscher Taschenbuchverlag (DTV), 2003
43. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998; 159 (5): 457-465
44. Rote Liste Win®. ECV Editio Cantor Verlag, 2003/II
45. Konsens GH. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens. Ges Ökon Qual Manag 1999; 4: 62-65
46. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13 (5): 437-452
47. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363 (9427): 2105-2115
48. Kaduszkiewicz H, Beck-Bornholdt HP, Bussche H van den, Zimmermann T. Fragliche Evidenz für den Einsatz des Cholinesterasehemmers Donepezil bei demenziellen Erkrankungen - eine systematische Übersicht. Fortschr Neurol Psychiatr 2004; 72 (10): 557-563
49. Hampel H, Uhl D. Acetylcholinesterasehemmer ohne Nutzen? Dtsch Apoth Ztg 2004; 144 (34): 34-37